Why These 15 Stocks Are Skyrocketing in 2025

Page 5 of 14

10. Summit Therapeutics (NASDAQ:SMMT)

Number of Hedge Fund Holders In Q3 2024: 21

Summit Therapeutics (NASDAQ:SMMT) is a biopharmaceutical company. It focuses on oncology and has therapies for non-small cell lung cancer.

The lead product here is ivonescimab, which is a bispecific antibody designed to block PD-1 and inhibit VEGF. The company has already reached multiple Phase III studies after the HARMONi banner in patients with EGFR-mutated NSCLC who have progressed after TKI therapy.

SMMT stock has risen significantly so far in 2025 due to it completing enrollment for its HARMONi Phase III trial and announcing that the FDA granted it fast-track designation for ivonescimab. This fueled a lot of optimism around the company.

Moreover, Summit Therapeutics has a cash reserve of around $410 million. That said, it is still pre-revenue, with a net loss of $56.3 million.

The average analyst price target is at $35.4, implying 49% upside.

SMMT stock is up 29.6% year-to-date.

Page 5 of 14